Abbott and Berlex Shake Up Contrast Media Even More
Executive Summary
For the last several months, the contrast media industry has all but turned on its head as the impending loss of patent on several key products has left the main players scrambling. For smaller competitor Berlex, the challenge was creating a broad enough product offering and distribution capability to play with the market leaders. Abbott provides a compelling presence to Berlex from the start with deep in-roads into the hospital market.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.